Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manon Allaire

Showing results (61-70 of 82) with videos related to

Pageof 9
Sort By:
JHEP Reports : Innovation in Hepatology|March 19, 2026
Atezolizumab-Bevacizumab in Very Elderly With Hepatocellular Carcinoma: Age Alone Is Not a Limiting Factor Except in ALBI Grade 3Chloé Métivier, Claudia Campani, Manon Allaire, et al.
Journal of Hepatology|February 7, 2026
Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinomaJean-Charles Nault, Claudia Campani, Theo Z Hirsch, et al.
Medrxiv : the Preprint Server for Health Sciences|December 3, 2025
Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular CarcinomaJean-Charles Nault, Claudia Campani, Theo Z Hirsch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2026
Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world dataClaudia Campani, Ju Hyun Shim, Mohamed Bouattour, et al.
Hepatology (Baltimore, Md.)|March 5, 2025
Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort studyBeat Moeckli, Charles-Henri Wassmer, Sofia El Hajji, et al.
JHEP Reports : Innovation in Hepatology|November 9, 2020
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence areaGiuliana Amaddeo, Raffaele Brustia, Manon Allaire, et al.
Annals of Hepatology|July 19, 2023
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later?Raffaele Brustia, Mohamed Bouattour, Manon Allaire, et al.
JHEP Reports : Innovation in Hepatology|June 11, 2026
Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinomaAnne Victoire Odent, Claudia Campani, Mohamed Bouattour, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 12, 2025
Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on ImmunotherapyMarta Fortuny, Leonardo G da Fonseca, Manon Allaire, et al.
BMC Gastroenterology|September 11, 2023
International survey among hepatologists and pulmonologists on the hepatic hydrothorax: plea for recommendationsJean-François David Cadranel, Isabelle Ollivier-Hourmand, Jacques Cadranel, et al.
Pageof 9

Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
JHEP Reports : Innovation in Hepatology|March 19, 2026
Atezolizumab-Bevacizumab in Very Elderly With Hepatocellular Carcinoma: Age Alone Is Not a Limiting Factor Except in ALBI Grade 3Chloé Métivier, Claudia Campani, Manon Allaire, et al.
Journal of Hepatology|February 7, 2026
Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinomaJean-Charles Nault, Claudia Campani, Theo Z Hirsch, et al.
Medrxiv : the Preprint Server for Health Sciences|December 3, 2025
Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular CarcinomaJean-Charles Nault, Claudia Campani, Theo Z Hirsch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2026
Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world dataClaudia Campani, Ju Hyun Shim, Mohamed Bouattour, et al.
Hepatology (Baltimore, Md.)|March 5, 2025
Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort studyBeat Moeckli, Charles-Henri Wassmer, Sofia El Hajji, et al.
JHEP Reports : Innovation in Hepatology|November 9, 2020
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence areaGiuliana Amaddeo, Raffaele Brustia, Manon Allaire, et al.
Annals of Hepatology|July 19, 2023
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later?Raffaele Brustia, Mohamed Bouattour, Manon Allaire, et al.
JHEP Reports : Innovation in Hepatology|June 11, 2026
Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinomaAnne Victoire Odent, Claudia Campani, Mohamed Bouattour, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 12, 2025
Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on ImmunotherapyMarta Fortuny, Leonardo G da Fonseca, Manon Allaire, et al.
BMC Gastroenterology|September 11, 2023
International survey among hepatologists and pulmonologists on the hepatic hydrothorax: plea for recommendationsJean-François David Cadranel, Isabelle Ollivier-Hourmand, Jacques Cadranel, et al.
Pageof 9